Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy

Stock Information for Avenue Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Avenue Therapeutics Inc.

Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit
Avenue Therapeutics to Participate in Upcoming Investor Conferences
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.